



COMPOSITION

Hyaluronic acid	25mg
DEAE Sephadex A25	25mg
[Cross linked with Butandiol-diglycidylether (BDDE)]	

DESCRIPTION

ReDexis® is a colorless, odorless, transparent and highly viscous aqueous gel, of synthetic origin. The gel is stored in a pre-filled disposable syringe. Each box contains a 1ml syringe of ReDexis® along with a sterilized 27g 13mm needle.

APPLICATION RANGE / INDICATIONS

ReDexis® is a cross linked hyaluronic acid gel that is indicated for the treatment of medium to deep lines and wrinkles of the face, by injection into the middle part of the dermis layer. Implantation life is dependant on depth and location of injection, and averages 12-18 months.

ANTICIPATED SIDE EFFECTS

Physicians must inform patients that with every injection of ReDexis® there are potential adverse reactions that may be delayed or occur immediately after the injection. These include but are not limited to:

- Injection-related reactions might occur, such as transient erythema, swelling, pain, itching, discoloration or tenderness at the injection site. These reactions may last for one week.
- Nodules or induration are also possible at the injection site.
- Poor product performance due to improper injection technique.
- Glabellar necrosis, abscess formation, granulomas and hypersensitivity have all been reported with injections of cross linked hyaluronic acid products. It is important for physicians to take these reactions into account on a case by case basis.

CONTRAINDICATIONS

- Do not inject into the lips or eye contours (into the eye circle or eyelids).
- Pregnant women, or women during lactation should not be treated with ReDexis®.
- ReDexis® should never be injected into blood vessels.
- Patients who develop hypertrophic scarring should not be treated with ReDexis®.
- Patients that have a known history of streptococcal disease.
- Never use ReDexis® in conjunction with a laser, intense pulsed light, chemical peeling or dermabrasion treatments.
- People under the age of 18 should not be treated with ReDexis®.
- Patients with acne and / or other inflammatory diseases of the skin should not be treated with ReDexis®.
- Patients with unattainable expectations.

► It is imperative that patients with adverse inflammatory reactions that persist for more than one week report this immediately to their physician. These conditions should be treated as appropriate (ie: corticosteroids or antibiotics). All other types of adverse reactions should be reported directly to the authorized distributor of the Revanesse® family of products and / or to Prolenium Medical Technologies Inc. directly.

ADMINISTRATION & DOSAGE

- ReDexis® should only be injected by or under the direct supervision of qualified physicians who have been trained on the proper injection technique for filling facial wrinkles.
- Before patients are treated they should be informed of the indications of the device as well as its contraindications and potential undesirable side effects.
- The area to be treated must be thoroughly disinfected.
- Be sure to inject only under sterile conditions.
- ReDexis® and needles packaged with it are for single use only. Do not re-use.
- Keep the product at room temperature for 30 minutes prior to injection.
- Inject slowly into the dermis using the linear tracking injection technique with the 27g needles that have been provided. The amount of ReDexis® that is injected per wrinkle will depend on its severity.
- If the skin turns a white color (blanching), the injection should be stopped immediately and the area should be massaged until the skin returns to its normal color.
- Before injecting, press on the plunger of the syringe until a small drop is visible at the tip of the needle.

PRECAUTIONS

- ReDexis® should not be injected into an area that already contains another filler product as there is no available clinical data on possible reactions.
- ReDexis® should not be injected into an area where there is a permanent filler or implant.
- Hyaluronic acid products have a known incompatibility with quarternary ammonium salts such as benzalkonium chloride. Please ensure that ReDexis® never comes into contact with this substance or medical instrumentation that has come into contact with this substance.

► **Note:** the correct injection technique is crucial to treatment success and patient satisfaction. ReDexis® should only be injected by a practitioner qualified according to local laws and standards.

- Avoid touching the treated area for 12 hours after injection and avoid prolonged exposure to sunlight, UV, as well as extreme cold and heat.
- Until the initial swelling and redness have resolved, do not expose the treated area to intense heat (e.g. solarium and sunbathing) or extreme cold.
- If you have previously suffered from facial cold sores, there is a risk that the needle punctures could contribute to another eruption of cold sores.
- If you are using aspirin or any similar medications be aware that these may increase bruising and bleeding at the injection site.

WARNINGS



- Confirm that the seal on the box has not been broken and sterility has not been compromised.
- Confirm that the product has not expired.
- Product is for single use only; do not re-use.

SHELF LIFE & STORAGE



Expiry is indicated on each individual package. Store between 2° - 25° C, and protect from direct sun light and freezing.

MANUFACTURER

Prollenium Medical Technologies Inc.
10670 Yonge St.
Richmond Hill, Ont, CANADA
L4C 3C9

t: +1 (905) 508.1469
f: +1 (905) 508.6716

W: www.prollenium.com
e: info@prollenium.com

	Emergo Europe Molenvaart 15 2615 BH, The Hague The Netherlands Tel: (+31) 70 345 6570 Fax: (+31) 70 346 7229	Authorized representative in Europe
	Lot number/batch number	
	Read instruction/product insert before use	
	Expiry date	
	Do not reuse – For single use only	
	Needle Sterilization by EO	
	Moist heat sterilization	
	Storage temperature (store between the temperatures of)	
	Manufacturing date	
	CE marking according to MDD 93/42/CEE 0086 is the number of the notified body	